Hinge Health, Inc. (HNGE) - Stock Analysis

Last updated: May 9, 2026

HealthcareActive

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Healthcare momentum candidate with strong execution: Q1 revenue was $182M, up 47% YoY and ahead of expectations, margins improved, management raised full-year revenue guidance, and Q1 free cash flow was $41.6M. Stock is up about 25% over the last 21 trading days with only a modest pullback from its recent high.

Loading chart data...

Idea window: 5/14/2026 – 5/21/2026Sector: Healthcare

AI Analyst Overview

Last Price
$53.88
Market Cap
$4.24B
1D Return
-0.33%
YTD Return
+16.00%

Loading chart data...

Valuation Metrics

P/E
-8.4
P/B
13.8
P/S
6.5
EV/EBITDA
-8.2
Div Yield
—

Fundamental Analysis

8.0

Key Financial Insights: • Cash Generation • Margin Strength • SBC Drag HNGE showed a sharp quarterly turnaround with strong gross margins, positive cash flow, and manageable debt, but annual losses, heavy stock-based compensation, and a still-rich valuation remain key risks.

Profitable
Valuation

Price Behavior

7.0

Key Price Behavior Insights: • Higher highs • Breakout hold • Stretched momentum Support Level: $49.75-$48.89 Resistance Level: $45-$46 HNGE's last month trend is strongly bullish, with a breakout above $45-$46 and support now at $49.75-$48.89, though the sharp run from the mid-$40s to $56.02 leaves it stretched and vulnerable to a pause.

breakout
extended

Sentiment & News

8.0

Key News Insights: • Revenue surge • Guidance raise • Migraine launch Hinge Health posted record Q1 2026 results with 47% revenue growth, margin expansion, and raised full-year guidance, while also expanding into migraine care and drawing stronger investor attention.

Growth
Expansion
AI

AI Summary

8.0
Positive

HNGE now looks less like a speculative digital health growth story and more like a scalable cash-generating business, with Q1 showing strong revenue growth, 84.5% gross margin, and real free cash flow—but the stock likely needs continued >40% growth and disciplined control of stock-based compensation/dilution to justify the rerating.

FCF
Dilution
Execution
AI summary updated 5 days ago

Description

Hinge Health develops software for musculoskeletal care, providing digital programs and services that support treatment of acute injuries, chronic pain and post-operative rehabilitation. The company also offers administrative and operational support to health plans and employers. Founded in 2012, it is headquartered in San Francisco, California.

Idea History

DateCloseTickerCompanySummaryStatusP/L
May 14May 21HNGEHinge Health, Inc.
Healthcare momentum candidate with strong execution: Q1 revenue was $182M, up 47% YoY and ahead of expectations, margins improved, management raised full-year revenue guidance, and Q1 free cash flow was $41.6M. Stock is up about 25% over the last 21 trading days with only a modest pullback from its recent high.
Active+0.0%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.